Adaptimmune Aims To Quickly Convert Teclera’s Accelerated Approval
The first engineered cell therapy for a solid tumor could be submitted for full approval in synovial sarcoma next year.
The first engineered cell therapy for a solid tumor could be submitted for full approval in synovial sarcoma next year.